Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 4(57), p. 1961-1964, 2013

DOI: 10.1128/aac.02184-12

Links

Tools

Export citation

Search in Google Scholar

Target Gene Sequencing To Define the Susceptibility of Neisseria meningitidis to Ciprofloxacin

Journal article published in 2013 by Eva Hong, Sara Thulin Hedberg, Sara Thulin Hedberg, Raquel Abad ORCID, Cecilia Fazio, Rocío Enríquez, Ala-Eddine Deghmane, Keith A. Jolley, Paola Stefanelli, Magnus Unemo, Julio A. Vazquez, Frédéric J. Veyrier, Muhamed-Kheir Taha
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Meningococcal gyrA gene sequence data, MICs, and mouse infection were used to define the ciprofloxacin breakpoint for Neisseria meningitidis . Residue T91 or D95 of GyrA was altered in all meningococcal isolates with MICs of ≥0.064 μg/ml but not among isolates with MICs of ≤0.032 μg/ml. Experimental infection of ciprofloxacin-treated mice showed slower bacterial clearance when GyrA was altered. These data suggest a MIC of ≥0.064 μg/ml as the ciprofloxacin breakpoint for meningococci and argue for the molecular detection of ciprofloxacin resistance.